SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) financials

SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]

Market Cap: ₹3,535Cr.
Current Price: ₹79.9
Stock P/E: 71.2
ROE: 28.9%
ROCE: 37.0%
Book Value: ₹2.81
Dividend Yield: 0.01%
52W High / Low: ₹84.2/26.3

In Sep 2026, SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) reported sales ₹44 Cr and net profit ₹16 Cr.

Annual TTM: sales ₹113 Cr, net profit ₹50 Cr.

Shareholding: Promoters 51.16% (Sep 2026), FIIs 0.43% (Sep 2026), DIIs 0.21% (Sep 2026), Public 48.20% (Sep 2026), No. of Shareholders 35,007% (Sep 2026).

SHUKRAPHAR quarterly results (₹ Cr.)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Sales	11	13	5	6	39	6	24	44
YoY Sales growth	-44%	+22%	+70%	+6%	+270%	-53%	+336%	+652%
Expenses	7	6	4	6	12	6	2	22
Operating Profit	4	7	1	-0	27	1	21	22
OPM %	37%	55%	24%	-7%	69%	11%	90%	50%
Other Income	1	1	1	2	1	1	1	1
Interest	0	0	0	0	0	0	0	0
Depreciation	1	1	1	1	1	1	1	1
Profit before tax	4	8	1	0	27	0	20	21
Tax %	23%	29%	26%	-1,090%	24%	568%	26%	24%
Net Profit	3	5	1	2	20	-2	15	16
EPS in Rs	0.07	0.12	0.02	0.05	0.46	-0.04	0.34	0.36
Raw PDF	—	—	—	—	—	—	—	—

SHUKRAPHAR profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	12	11	20	59	75	33	57	113
Sales growth	+109%	-6%	+83%	+187%	+27%	-56%	+74%	+222%
Expenses	10	10	18	53	55	20	28	42
Operating Profit	2	1	3	5	19	13	29	71
OPM %	13%	13%	14%	9%	26%	39%	51%	63%
Other Income	0	0	0	1	3	4	5	3
Interest	0	0	0	0	0	1	1	1
Depreciation	1	1	2	2	2	3	3	4
Profit before tax	0	0	1	4	20	13	29	69
Tax %	82%	-90%	26%	1%	7%	28%	23%	—
Net Profit	0	0	1	4	19	10	22	50
EPS in Rs	0.00	0.01	0.02	0.15	0.42	0.22	0.50	1.12
Dividend Payout %	0%	0%	10%	4%	6%	5%	2%	—

SHUKRAPHAR balance sheet (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Sep 2026
Equity Capital	2	2	2	4	11	44	44	44
Reserves	14	14	15	21	47	19	46	80
Borrowings	8	10	3	5	3	4	5	21
Other Liabilities	10	10	15	45	17	20	23	33
Total Liabilities	34	36	35	75	78	87	117	178
Fixed Assets	17	18	18	20	20	19	22	21
CWIP	2	2	2	2	2	2	12	26
Investments	0	0	0	0	0	0	0	0
Other Assets	14	16	16	53	56	65	84	131
Total Assets	34	36	35	75	78	87	117	178

SHUKRAPHAR cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	0	1	1	8	3	-5	8	3
Cash from Investing Activity	-2	-3	-2	-2	-4	-1	-1	-14
Cash from Financing Activity	2	2	2	-7	5	12	-5	5
Net Cash Flow	0	-0	0	-0	4	6	2	-6
Free Cash Flow	-2	-2	-1	6	-1	-7	5	-13
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	25%	81%	38%	292%	64%	-24%	92%	17%

SHUKRAPHAR shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	50.95%	50.95%	50.95%	50.95%	50.95%	50.95%	50.95%	51.16%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.43%
DIIs	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.21%
Public	48.93%	48.93%	48.93%	48.93%	48.93%	48.92%	48.93%	48.20%
No. of Shareholders	17,844	18,231	20,337	21,441	25,649	27,173	28,384	35,007

SHUKRAPHAR key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	345	245	318	132	187	120	98	148
Inventory Days	100	169	221	139	25	19	447	320
Days Payable	1,161	786	702	303	271	59	414	232
Cash Conversion Cycle	-717	-372	-163	-32	-58	80	131	236
Working Capital Days	440	226	278	57	41	157	403	352
ROCE %	4%	0%	1%	6%	19%	44%	22%	37%

SHUKRAPHARUpdated 7 Nov 2026, 22:37

Shukra Pharmaceuticals L

SHUKRAPHARUpdated 7 Nov 2026, 22:37

Market Cap

₹3,535Cr.

Current Price

₹79.9

High / Low

₹84.2/26.3

Stock P/E

71.2

ROE28.9%

ROCE37.0%

Book Value₹2.81

Face Value₹1.00

Dividend Yield0.01%

About

Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Sep 2023	25	20	0	1	5	0	5	0.11
Dec 2023	19	9	1	1	10	1	9	0.22
Mar 2024	11	6	1	1	5	24	4	0.09
Jun 2024	3	2	1	1	1	41	0	0.01
Sep 2024	6	5	1	1	1	39	1	0.01
Dec 2024	11	7	1	1	4	23	3	0.07
Mar 2025	13	6	1	1	8	29	5	0.12
Jun 2025	5	4	1	1	1	26	1	0.02
Sep 2025	6	6	2	1	0	-1090	2	0.05
Dec 2025	39	12	1	1	27	24	20	0.46
Mar 2026	6	6	1	1	0	568	-2	-0.04
Jun 2026	24	2	1	1	20	26	15	0.34
Sep 2026	44	22	1	1	21	24	16	0.36

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	3	0	3	1	1	0	52	0	0
Mar 2016	5	0	4	0	0	0	66	0	0
Mar 2017	5	0	4	0	0	1	52	0	0.02
Mar 2018	5	0	4	0	1	1	45	1	0.02
Mar 2019	6	0	4	0	1	1	37	0	0.02
Mar 2020	12	0	10	0	1	0	82	0	0
Mar 2021	11	0	10	0	1	0	-90	0	0.01
Mar 2022	20	0	18	0	2	1	26	1	0.02
Mar 2023	59	0	53	1	2	4	1	4	0.15
Mar 2024	75	0	55	3	2	20	7	19	0.42
Mar 2025	33	1	20	4	3	13	28	10	0.22
Mar 2026	57	1	28	5	3	29	23	22	0.5
TTM	113	1	42	3	4	69	—	50	1.12

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	51.16%
FIIs	0.43%
DIIs	0.21%
Public	48.2%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	50.95%	0%	0.11%	48.93%
Mar 2024	50.95%	0%	0.11%	48.93%
Jun 2024	50.95%	0%	0.11%	48.93%
Sep 2024	50.95%	0%	0.11%	48.93%
Dec 2024	50.95%	0%	0.11%	48.93%
Mar 2025	50.95%	0%	0.11%	48.93%
Jun 2025	50.95%	0%	0.11%	48.93%
Sep 2025	50.95%	0%	0.11%	48.93%
Dec 2025	50.95%	0%	0.11%	48.93%
Mar 2026	50.95%	0%	0.11%	48.92%
Jun 2026	50.95%	0%	0.11%	48.93%
Sep 2026	51.16%	0.43%	0.21%	48.2%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Other Assets	Total Assets
Mar 2015	2	12	1	3	18	10	2	7	18
Mar 2016	2	13	0	3	17	10	2	6	17
Mar 2017	2	13	0	4	19	10	2	7	19
Mar 2018	2	13	4	6	24	14	2	8	24
Mar 2019	2	14	6	7	28	16	2	11	28
Mar 2020	2	14	8	10	34	17	2	14	34
Mar 2021	2	14	10	10	36	18	2	16	36
Mar 2022	2	15	3	15	35	18	2	16	35
Mar 2023	4	21	5	45	75	20	2	53	75
Mar 2024	11	47	3	17	78	20	2	56	78
Mar 2025	44	19	4	20	87	19	2	65	87
Mar 2026	44	46	5	23	117	22	12	84	117
Sep 2026	44	80	21	33	178	21	26	131	178

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	-2	1	1	0
Mar 2016	3	0	-1	1
Mar 2017	0	-1	0	-1
Mar 2018	1	-5	3	0
Mar 2019	0	-2	2	0
Mar 2020	1	-3	2	0
Mar 2021	1	-2	2	0
Mar 2022	8	-2	-7	0
Mar 2023	3	-4	5	4
Mar 2024	-5	-1	12	6
Mar 2025	8	-1	-5	2
Mar 2026	3	-14	5	-6

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	73	71	175	200	345	245	318	132	187	120	98	148
Inventory Days	554	92	112	53	100	169	221	139	25	19	447	320
Days Payable	291	108	400	734	1,161	786	702	303	271	59	414	232
Cash Conversion Cycle	335	54	-112	-480	-717	-372	-163	-32	-58	80	131	236
Working Capital Days	758	258	344	379	440	226	278	57	41	157	403	352
ROCE %	-1%	6%	7%	6%	4%	0%	1%	6%	19%	44%	22%	37%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of SHUKRA PHARMACEUTICALS L (SHUKRAPHAR)?

The reported market capitalisation for SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) is ₹3,535Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of SHUKRAPHAR?

The current price shown for SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) on Fincrux is ₹79.9 with a 52-week high/low of ₹84.2/26.3.

What is the P/E ratio of SHUKRA PHARMACEUTICALS L (SHUKRAPHAR)?

The stock P/E for SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) is 71.2 on Fincrux, with ROE at 28.9% and ROCE at 37.0%.

What were SHUKRAPHAR latest quarterly results?

For Sep 2026, SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) reported sales ₹44 Cr and net profit ₹16 Cr (figures in ₹ crore unless noted).

What are SHUKRAPHAR annual sales and net profit?

For TTM, SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) shows sales of ₹113 Cr and net profit of ₹50 Cr on the Fincrux profit & loss statement.

Who owns SHUKRA PHARMACEUTICALS L (SHUKRAPHAR)?

Latest shareholding for SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) on Fincrux: Promoters 51.16% (Sep 2026), FIIs 0.43% (Sep 2026), DIIs 0.21% (Sep 2026), Public 48.20% (Sep 2026), No. of Shareholders 35,007% (Sep 2026).

Where can I find SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) financials?

SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show SHUKRAPHAR balance sheet and cash flow?

Yes. The SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 7 November 2026 at 22:37